



# ADDING THE RISKGUARD™ TEST GIVES YOU POWERFUL INFORMATION

\*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. [#52215]

†The patient's risk of recurrence at 9 years if taking endocrine therapy alone.

Information provided is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

These tests were developed, and the performance characteristics validated by Exact Sciences Laboratories and/or wholly owned subsidiaries of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. These tests have not been cleared or approved by the US Food and Drug Administration. For more information on each test, see [ExactSciences.com](https://ExactSciences.com).

### References

<sup>1</sup>Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed April 30, 2024. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://NCCN.org).

<sup>2</sup>Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed April 30, 2024. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://NCCN.org).

Scan the QR code to learn more about the Riskguard™ test or visit: [ExactSciences.com/Riskguard](https://ExactSciences.com/Riskguard)



# EXACT SCIENCES

## PATIENT CLINICAL PROFILE



Not an actual patient

Age **56**

### Personal diagnosis

- Breast cancer:
- Tumor size: 2.0cm
  - HR+ / HER2-
  - Lymph node [-]

### Family history

Sister with ovarian cancer

# WHAT TESTS WOULD YOU INCLUDE IN THIS PATIENT'S WORKUP?



# EXACT SCIENCES

Riskguard and Exact Sciences are trademarks of Exact Sciences Corporation. Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. M-US-HCT-00110.

Recurrence Score<sup>®</sup> (RS) Result

13

Distant Recurrence Risk at 9 Years

With AI or TAM Alone

4%

95% CI (3%, 5%)

TAILORx

AI = Aromatase Inhibitor / TAM = Tamoxifen  
CI = Confidence Intervals

Group Average Absolute Chemotherapy  
(CT) Benefit

RS 11-25 All Ages

<1%

95% CI (-1%, 2%)

TAILORx

Example Oncotype DX Breast Recurrence Score<sup>®</sup> results



Patient meets criteria for hereditary cancer testing due to her family history of ovarian cancer

Summary findings

**+** Positive

Clinically actionable results

Results

Sequence variant(s):

**BRCA1** NM\_007294.3:c.66dup, p.Glu23Argfs\*18 Heterozygous Pathogenic

Example Riskguard<sup>™</sup> results

The Riskguard<sup>™</sup> test shows this patient is positive for a *BRCA1* variant, which may help further inform potential treatment and prevention options, such as the following recommended by the National Comprehensive Cancer Network<sup>®</sup> (NCCN)<sup>\*1,2</sup>:

**Breast cancer**

- Discuss surgical options, including bilateral mastectomy, or screening with annual mammogram and breast MRI after treatment
- PARPi (1st line - metastatic)

**Ovarian cancer**

- Recommend Risk-Reducing Salpingo-Oophorectomy (RRSO)
- Discuss concurrent hysterectomy at time of RRSO

The care options above are general guidelines and not meant to be comprehensive or specific to any patient.

oncotype dx<sup>®</sup>

Breast Recurrence Score

The Oncotype DX<sup>®</sup> test can help you understand certain risks and benefits

- What is the risk of recurrence?<sup>†</sup>
- What is the absolute benefit of chemotherapy?

riskguard<sup>™</sup>

Hereditary Cancer Test

The addition of the Riskguard<sup>™</sup> test can help further inform patient care

- Does my patient have a variant that could make them eligible for a targeted therapy?
- Should my patient have additional screening and/or risk-reducing treatments?
- Are the patient's family members at higher risk?